Core Laboratories (CLB) Net Income towards Common Stockholders (2022 - 2026)

Core Laboratories has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$704000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1120.29% year-over-year to -$704000.0; the trailing twelve-month figure through Mar 2026 stood at $29.6 million (up 2.84% YoY), and the FY2025 full-year result was $30.4 million, down 5.48% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$704000.0, down from $5.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $23.0 million in Q2 2023, with the low at -$704000.0 in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $7.5 million across 5 years, with a median of $7.3 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 220.99% — and 2026, when it tumbled 1120.29%.
• Core Laboratories' Net Income towards Common Stockholders stood at $6.0 million in 2022, then plunged by 59.32% to $2.4 million in 2023, then surged by 208.59% to $7.5 million in 2024, then tumbled by 31.71% to $5.1 million in 2025, then sank by 113.73% to -$704000.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$704000.0 (Q1 2026), $5.1 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.